Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis

Hypertension

Volumn 47, Issue 5, 2006, Pages 1003-1009

  Sugimoto, Ken ^a,b   Qi, Nathan R ^a   Kazdová, Ludmila ^c   Pravenec, Michal ^d   Ogihara, Toshio ^b   Kurtz, Theodore W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^d INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

Angiotensin II; Hypertension; Liver; Obesity; Receptors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; MITOCHONDRIAL PROTEIN; NUCLEAR PROTEIN; TELMISARTAN; TRIACYLGLYCEROL; VALSARTAN; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY FAT DISTRIBUTION; CARBOHYDRATE DIET; CELL SIZE; CELL VOLUME; CONTROLLED STUDY; DRUG EFFECT; ENERGY EXPENDITURE; ENERGY METABOLISM; FATTY LIVER; FOOD INTAKE; GENE EXPRESSION; GENETIC CODE; LIPID DIET; LIPID LIVER LEVEL; LIPID STORAGE; LIVER PROTECTION; MALE; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; WEIGHT CHANGE; WEIGHT GAIN; ADIPOSE TISSUE; ANIMAL; CELL COUNT; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ADIPOCYTES; ADIPOSE TISSUE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; CELL COUNT; CELL SIZE; ENERGY METABOLISM; FATTY LIVER; GENE EXPRESSION; MALE; MITOCHONDRIA; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES; VALINE; WEIGHT GAIN;

EID: 33646148948     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000215181.60228.f7     Document Type: Article

References (24)

1. Pi-Sunyer FX. The epidemiology of central fat distribution in relation to disease. Nutr Rev. 2004;62:S120-S126.
2. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, Mohammed BS. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350:2549-2557.
3. Gabriely I, Barzilai N. Surgical removal of visceral adipose tissue: effects on insulin action. Curr Diab Rep. 2003;3:201-206.
4. Kawai T, Takei I, Oguma Y, Ohashi N, Tokui M, Oguchi S, Katsukawa F, Hirose H, Shimada A, Watanabe K, Saruta T. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism: Clin. Exp. 1999;48:1102-1107.
5. Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC, Kern PA. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab. 2005;288:E930-E934.
6. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 1998;101:1354-1361.
7. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension. 2004;43:993-1002.
8. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation. 2004;109:2054-2057.
9. Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, Biswas C, Parikh M, Sharma N, Tanen MR, Thompson GM, Ventre J, Adams AD, Mosley R, Surwit RS, Moller DE. Distinct properties and advantages of a novel peroxisome proliferator- activated protein {γ} selective modulator. Mol Endocrinol. 2003;17:662-676.
10. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension. 2002;40:609-611.
11. Simonson DC, DeFronzo RA. Indirect calorimetry: methodological and interpretative problems. Am J Physiol. 1990;258:E399-E412.
12. Fine JB, DiGirolamo M. A simple method to predict cellular density in adipocyte metabolic incubations. Int J Obes Relat Metab Disord. 1997;21:764-768.
13. Kang D, Hamasaki N. Mitochondrial transcription factor a in the maintenance of mitochondrial DNA: overview of its multiple roles. Ann N Y Acad Sci. 2005;1042:101-108.
14. Ekstrand MI, Falkenberg M, Rantanen A, Park CB, Gaspari M, Hultenby K, Rustin P, Gustafsson CM, Larsson NG. Mitochondrial transcription factor A regulates mtDNA copy number in mammals. Hum Mol Genet. 2004;13:935-944.
15. Garnier A, Fortin D, Delomenie C, Momken I, Veksler V, Ventura-Clapier R. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol. 2003;551:491-501.
16. Qi NR, Wang J, Zidek V, Landa V, Mlejnek P, Kazdova L, Pravenec M, Kurtz TW. A new transgenic rat model of hepatic steatosis and the metabolic syndrome. Hypertension. 2005;45:1004-1011.
17. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30:e36.
18. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor {γ} modulators with angiotensin receptor blocking activity. Diabetes. 2005;54:3442-3452.
19. Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, Fujikura J, Chusho H, Ebihara K, Hayashi T, Hosoda K, Nakao K. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 2004;576:492-497.
20. Krempl T, Schwedhelm E, Hornung D, Schmid B, Schieffer B, Boeger R. Identification of EXP 3179 as selective PPAR γ receptor agonist. Zeitschrift fur Kardiologie. 2005;94:V62.
21. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Kadowaki T. PPAR γ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell. 1999;4:597-609.
22. Burgermeister E, Schnoebelen A, Flament A, Benz J, Blum D, Kuhn B, Marki HP, Mizrahi J, Niesor E, Meyer M. A common theme for partial peroxisome proliferator-activated receptor-γ agonists: Recruitment of PPAR-γ coactivator-1 α, a central regulator of energy expenditure. 3rd International Symposium on PPARs. 2005:19 (abstract).
23. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-γ coactivator 1 alpha (PGC-1 α): transcriptional coactivator and metabolic regulator. Endocr Rev. 2003;24:78-90.
24. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, Bolondi L. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 2004;53:1020-1023.